.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

A Multidisciplinary Approach to CAR T-cell Therapy for Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

EP. 1: CAR T-cell Therapy for B-ALL

December 24th 2024

A panelist discusses how CAR-T cell therapy patient selection involves evaluating disease characteristics like relapse/refractory status and tumor burden, patient-specific factors including performance status and organ function, with extramedullary disease requiring careful monitoring while isolated CNS disease may warrant alternative treatments or clinical trials.